Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort.


Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
Historique:
received: 16 03 2021
accepted: 17 06 2021
pubmed: 14 9 2021
medline: 17 5 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

There is growing evidence of gender-specific phenotypic differences among patients with idiopathic pulmonary fibrosis (IPF), which may affect patient outcomes. We present the characteristics of patients with IPF at inclusion in the French Rare Disease Cohort - Interstitial Lung Disease (RaDiCo-ILD) with the aim of characterizing gender-specific phenotypic differences. Patients with IPF who were enrolled in the national, multicentre RaDiCo-ILD cohort were included. Demographic characteristics, comorbidities, health-related quality of life (HRQoL) scores, pulmonary function, chest imaging, and IPF treatment were collected at inclusion and described by gender. The cohort included 724 patients with IPF (54% of RaDiCo-ILD cohort), of whom 82.9% were male. The proportion of male and female patients with a prior history of smoking was 75.0% and 26.8%, respectively. Emphysema was present in 17.0% (95% confidence interval [CI]: 10.0, 24.0) of men and 5.4% (95% CI: 1.2, 9.6) of women. At inclusion, females had poorer HRQoL than males based on St. George's Respiratory Questionnaire scores (48.5 [95% CI: 43.9, 53.0] and 41.5 [39.4, 43.6], respectively). The mean forced vital capacity per cent predicted was 77.7% (95% CI: 76.2, 79.3) and 87.4% (83.4, 91.4) for males and females, respectively. Honeycombing on high-resolution computed tomography (HRCT) was present in 70.8% (95% CI: 61.0, 80.6) of males and 45.8% (95% CI: 35.1, 56.5) of females. This analysis of patients with IPF at inclusion in the RaDiCo-ILD cohort provides evidence that comorbid emphysema, lung volume reduction, and honeycombing on HRCT are more common characteristics of males than females.

Sections du résumé

BACKGROUND BACKGROUND
There is growing evidence of gender-specific phenotypic differences among patients with idiopathic pulmonary fibrosis (IPF), which may affect patient outcomes.
OBJECTIVES OBJECTIVE
We present the characteristics of patients with IPF at inclusion in the French Rare Disease Cohort - Interstitial Lung Disease (RaDiCo-ILD) with the aim of characterizing gender-specific phenotypic differences.
METHODS METHODS
Patients with IPF who were enrolled in the national, multicentre RaDiCo-ILD cohort were included. Demographic characteristics, comorbidities, health-related quality of life (HRQoL) scores, pulmonary function, chest imaging, and IPF treatment were collected at inclusion and described by gender.
RESULTS RESULTS
The cohort included 724 patients with IPF (54% of RaDiCo-ILD cohort), of whom 82.9% were male. The proportion of male and female patients with a prior history of smoking was 75.0% and 26.8%, respectively. Emphysema was present in 17.0% (95% confidence interval [CI]: 10.0, 24.0) of men and 5.4% (95% CI: 1.2, 9.6) of women. At inclusion, females had poorer HRQoL than males based on St. George's Respiratory Questionnaire scores (48.5 [95% CI: 43.9, 53.0] and 41.5 [39.4, 43.6], respectively). The mean forced vital capacity per cent predicted was 77.7% (95% CI: 76.2, 79.3) and 87.4% (83.4, 91.4) for males and females, respectively. Honeycombing on high-resolution computed tomography (HRCT) was present in 70.8% (95% CI: 61.0, 80.6) of males and 45.8% (95% CI: 35.1, 56.5) of females.
CONCLUSIONS CONCLUSIONS
This analysis of patients with IPF at inclusion in the RaDiCo-ILD cohort provides evidence that comorbid emphysema, lung volume reduction, and honeycombing on HRCT are more common characteristics of males than females.

Identifiants

pubmed: 34515219
pii: 000518008
doi: 10.1159/000518008
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-45

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Vincent Cottin (V)

Hôpital Louis Pradel, Centre Coordinateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754, Université de Lyon, INRAE, OrphaLung, RespiFil, Lyon, France.

Sonia Gueguen (S)

Inserm U933, RaDiCo, French National Program on Rare Disease Cohorts, Hôpital Trousseau, Paris, France.

Stéphane Jouneau (S)

Hôpital Pontchaillou - CHU de Rennes, IRSET UMR 1085, Université de Rennes 1, Rennes, France.

Hilario Nunes (H)

Assistance Publique Hôpitaux de Paris, Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares (Site Constitutif), Hôpital Avicenne, Inserm UMR1272, Université Sorbonne Paris Nord, Bobigny, France.

Bruno Crestani (B)

Université de Paris, Inserm U1152, Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Centre de Référence (Site Constitutif) Maladies Pulmonaires Rares, Paris, France.

Philippe Bonniaud (P)

Centre de Référence (Site Constitutif) Maladies Pulmonaires Rares, Service de Pneumologie et Soins Intensifs Respiratoires, CHU Dijon-Bourgogne, Université Bourgogne-Franche Comté, Inserm U1231, Dijon, France.

Lidwine Wémeau-Stervinou (L)

Service de Pneumologie et Immuno-Allergologie, Centre de Référence (Site Constitutif) Maladies Pulmonaires Rares, CHU de Lille, Lille, France.

Martine Reynaud-Gaubert (M)

Service de Pneumologie, CHU Marseille secteur Nord, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.

Dominique Israël-Biet (D)

Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Pneumologie, Université de Paris, Paris, France.

Jacques Cadranel (J)

Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Oncologie Thoracique, Centre de Référence (Site Constitutif) Maladies Pulmonaires Rares, Hôpital Tenon and Sorbonne Université, Paris, France.

Sylvain Marchand-Adam (S)

Université François Rabelais, Inserm U1100, Service de Pneumologie, CHRU de Tours, Tours, France.

Sébastien Quétant (S)

Service Hospitalo-Universitaire de Pneumologie et Physiologie, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire de Grenoble-Alpes, La Tronche, France.

Sandrine Hirschi (S)

Service de Pneumologie, Centre Hospitalier Universitaire (CHU) Strasbourg, Strasbourg, France.

David Montani (D)

Université Paris - Saclay, Assistance Publique Hôpitaux de Paris, Inserm UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.

Anne-Sophie Gamez (AS)

Service de Pneumologie, CHU Montpellier, Montpellier, France.

Marie Chevereau (M)

Inserm U933, RaDiCo, French National Program on Rare Disease Cohorts, Hôpital Trousseau, Paris, France.

Isabelle Dufaure-Garé (I)

Inserm U933, RaDiCo, French National Program on Rare Disease Cohorts, Hôpital Trousseau, Paris, France.

Serge Amselem (S)

Sorbonne Université, Inserm U933, RaDiCo, French National Program on Rare Disease Cohorts, Hôpital Trousseau, Paris, France.

Annick Clement (A)

Sorbonne Université, Assistance Publique Hôpitaux de Paris, Hôpital Trousseau, Service de Pneumologie Pédiatrique, Centre de Référence des Maladies Respiratoires Rares, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH